Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) CIDP is a rare and serious autoimmune disease of the peripheral nervous system.

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...